Advertisement

Locoregional Radionuclide Therapy for Nonmelanoma Skin Cancer (NMSC)

  • F. F. (Russ) Knapp
  • Ashutosh Dash
Chapter

Abstract

The incidence of skin cancer continues to rapidly increase, especially in the Western world. Melanoma is the most dangerous because of its often undiagnosed presence and metastatic potential and can have a 5-year survival rate of only about 98 %, if detected early before the cancer has penetrated the skin. After metastasis to other organs, however, the survival rate can be as low as 15 %. About 90 % of nonmelanoma skin cancers (NMSC) are estimated to result directly from ultraviolet radiation from sun exposure and primarily consist of the common basal cell (BCC) and squamous cell carcinomas (SCC) which often result from actinic keratosis precancers. These cancers can usually be effectively eradicated by surgery and local radiation treatment. However, scarring and disfigurement, especially on the face, are major issues. A new method using topical application of beta-emitting radionuclides has been introduced as an attractive, inexpensive, and effective alternative.

Keywords

Skin Cancer Basal Cell Carcinoma Natural Rubber Skin Patch Nonmelanoma Skin Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Anteby I, Axer-Siegel R, Pe’er J. Choroidal metastasis of cutaneous malignant melanoma treated by ruthenium-106 plaque irradiation. Ann Opthalmol. 1993;25(9):339–41.Google Scholar
  2. Carrozzo AM, Sedda AF, Muscardin L, et al. Dermo beta brachytherapy with 188-Re in squamous-cell carcinoma of penis: a new therapy. Eur J Dermatol. 2013a;23(2):183–8.PubMedGoogle Scholar
  3. Carrozzo AM, Cipriani C, Donati P, et al. Dermo beta brachytherapy with 188-Re in extramammary Paget’s disease. G Ital Dermatol Venereol. 2013b;148:1–2.Google Scholar
  4. Chung YL, Lee JD, Bang D, et al. Treatment of Bowen’s disease with a specially designed radioactive skin patch. Eur J Nucl Med. 2000;27(7):842–6.PubMedCrossRefGoogle Scholar
  5. Cipriani C. Applicator for applying a radioactive substance to a biological sample. US Patent Application 2013/0,006,033, 6 Nov 2010. 2010.Google Scholar
  6. Cipriani C, Desantis M. Brachytherapy method of treating skin tumors using a tailor-made radioactive source. US Patent Application 2011/0,201,866, 18 Aug 2011. 2011.Google Scholar
  7. Gupta P, Malhotra A, Saxena S, et al. Radionuclide therapy of basal cell carcinoma with phosphorus-32 skin patch. J Nucl Med. 2009;50(Suppl):15.Google Scholar
  8. Jeong JM, Lee YL, Kim EH, et al. Preparation of 188Re-labeled paper for treating skin cancer. Appl Radiat Isot. 2003;58:551–5.PubMedCrossRefGoogle Scholar
  9. Lee JD, Park KK, Lee MG, et al. Radionuclide therapy of skin cancer and Bowen’s disease using a specially designed skin patch. J Nucl Med. 1997;38(5):697–702.PubMedGoogle Scholar
  10. Lock M, Cao JQ, D’Souza DP, et al. Brachytherapy with permanent gold grain seeds for squamous cell carcinoma of the lip. Radiother Oncol. 2011;98(3):353–6.CrossRefGoogle Scholar
  11. Mowlavi AA, Afzalifar A, Afzalibar N, et al. Depth dose calculation of holmium-166 for different shape by VARSKIN3 code. Iran J Nucl Med. 2010;18(1):32–6.Google Scholar
  12. Mukherjee A, Pandey U, Sarma HD, et al. Preparation and evaluation of 90Y skin patches for therapy of superficial tumors in mice. Nucl Med Commun. 2002;23(3):243–7.Google Scholar
  13. Mukherjee A, Pandhey U, Sarma HD, et al. Bioevaluation of radioactive bandages in a murine model of melanoma. Int J Radiat Biol. 2003;79:839–45.PubMedCrossRefGoogle Scholar
  14. Pandey U, Saxena SK, Sarma HD, et al. Bioevaluation studies of 32P incorporated mould brachytherapy sources for potential application in treatment of superficial tumors. Nucl Med Comm. 2008a;29(8):717–23.CrossRefGoogle Scholar
  15. Pandey U, Sarma HD, Ingle AD, et al. Radioactive skin bandages incorporating 32P for treatment of superficial tumors. Can Biother Radiopharm. 2008b;21(3):257–62.CrossRefGoogle Scholar
  16. Rogers HW, Wienstock MA, Harris AR, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol. 2010;146(3):283–7.PubMedCrossRefGoogle Scholar
  17. Rustgi SN, Cumberlin RL. An afterloading 192Ir surface mold. Med Dosim. 1993;18(1):39–42.PubMedGoogle Scholar
  18. Saho S, Palani T, Saxena SK, et al. Monte Carlo-based dose calculation for 32P patch source for superficial brachytherapy applications. J Med Phys. 2015;40(1):13–7.CrossRefGoogle Scholar
  19. Salgueiro MJ, Duran H, Palieri M, et al. Design and bioevaluation of a 32P-patch for brachytherapy of skin diseases. Appl Radiat Isot. 2008a;66(3):303–9.PubMedCrossRefGoogle Scholar
  20. Salgueiro MJ, Duran H, Palmieri M, et al. Bioevaluation of 32P patch designed for the treatment of skin diseases. Nucl Med Biol. 2008b;35(2):233–7.PubMedCrossRefGoogle Scholar
  21. Salgueiro MJ, Collia M, Barreiro ML, et al. Radioactive treatment of a murine melanoma using a 32P patch. Nucl Med Commun. 2009a;30(9):706–12.PubMedCrossRefGoogle Scholar
  22. Salgueiro MJ, Collia M, Duran H, et al. Biological effects of brachytherapy using a 32P-atch on the skin of Sencar mice. Appl Radiat Isot. 2009b;67(10):1769–74.PubMedCrossRefGoogle Scholar
  23. Saxena SK, Kumar Y, Dash A. Nafion-Zirconium phosphate composite membrane: a new approach to prepare 32P patches for superficial brachytherapy applications. Can Biother Radiopharm. 2012;27(4):276–84.CrossRefGoogle Scholar
  24. Saxena SK, Pandey U, Kumar Y, et al. On the application of nafion membrane for the preparation of 90Y skin patches, quality control, and biological evaluation of treatment of superficial tumors. Can Biother Radiopharm. 2014;295:200–9.CrossRefGoogle Scholar
  25. Sedda AF, Rossi G, Desantis M, et al. DOBBIN (Distribution Optimization for Beta Brachytherapy Intratumor): a program for geometrical optimization of beta brachytherapy interstitial administration. In: V Italian Congress of Nuclear Medicine, Pesaro (Italy) 17–20 Jun 2000. 2000.Google Scholar
  26. Sedda AF, Rossi G, Cipriani C. Beta emitter multilayer for the dermatological brachytherapy of cutaneous tumors. In: European Association of Nuclear Medicine, annual congress, Amsterdam, September 2003. 2003.Google Scholar
  27. Sedda AF, Rossi G, Carrozzo AM, et al. Superficial brachytherapy with beta emitting isotopes for the treatment of basal cell carcinoma. In: 3rd meeting of the European Association of Dermato-Oncology (EADO), Rome, 23–25 June 2006. 2006.Google Scholar
  28. Sedda AF, Rossi G, Cipriani C, et al. Dermatological high-dose-rate brachytherapy for the treatment of basal and squamous cell carcinoma. Clin Exp Dermatol. 2008;33:745–9.PubMedCrossRefGoogle Scholar
  29. Shi CB, Yuan B, Lu JR, et al. Continuous low-dose-rate radiation of radionuclide phosphorus-32 for hemangiomas. Can Biother Radiopharm. 2012;27(3):198–203.CrossRefGoogle Scholar

Copyright information

© Springer India 2016

Authors and Affiliations

  • F. F. (Russ) Knapp
    • 1
  • Ashutosh Dash
    • 2
  1. 1.Nuclear Security and Isotope DivisionOak Ridge National LaboratoryOAK RIDGEUSA
  2. 2.Isotope Production and Applications DivisionBhabha Atomic Research CentreMumbaiIndia

Personalised recommendations